Wegovy is FDA-approved as a long-term medication, meaning there is no built-in stopping point. The label specifically says it is intended to “maintain weight reduction long term,” and most doctors prescribe it with the expectation that you’ll stay on it indefinitely. In practice, though, many people stop within the first year.
Why Wegovy Is Designed for Ongoing Use
Obesity is classified as a chronic condition, and Wegovy is approved to treat it the same way blood pressure or cholesterol medications treat those conditions: continuously. The FDA’s labeling makes no mention of a recommended duration or an endpoint where patients should taper off. Once you reach the full maintenance dose (a weekly injection), the expectation is that you continue at that dose to preserve your results.
This matters because weight regain after stopping is well-documented. Clinical trials have shown that people who discontinue semaglutide regain a significant portion of lost weight within a year. The drug works by reducing appetite and slowing digestion, and those effects disappear when you stop taking it. Your hunger signals return to baseline, and the metabolic changes that helped you lose weight reverse.
How Long People Actually Stay On It
Despite being designed for long-term use, a large gap exists between what’s recommended and what actually happens. Real-world data on GLP-1 medications in the same class as Wegovy shows that about 63% of patients are still taking their medication after 12 months. That means roughly one in three people stops within the first year.
Some estimates are even more striking. Researchers at Northwestern University have noted that 50 to 75% of people stop taking GLP-1 drugs within a year, depending on the population studied. The reasons vary, but they tend to cluster around a few key factors: cost, side effects, and the perception that the medication is temporary.
Why People Stop Early
Cost is the single biggest barrier. Wegovy carries a list price of over $1,300 per month, and insurance coverage is inconsistent. Many plans require prior authorization and impose renewal criteria. Johns Hopkins Health Plans, for example, reviews coverage in six-month intervals and requires documentation that you still meet the original prescribing criteria. If your insurance changes, your employer drops coverage for weight management drugs, or you hit a gap in authorization, you may lose access.
Side effects push some people off the medication earlier than planned. Nausea, vomiting, diarrhea, and constipation are common during the dose escalation phase (the first 16 to 20 weeks), and some people find them intolerable. The slow ramp-up schedule, which starts at a low dose and increases monthly, is specifically designed to minimize these effects, but not everyone can push through.
Perhaps the most underappreciated reason is mindset. Many people approach Wegovy the way they’d approach a course of antibiotics: take it until the problem is solved, then stop. They set a goal weight, reach it, and assume the job is done. Unlike medications for high blood pressure, which most people accept they’ll take for life, weight loss drugs still carry the expectation of being temporary. This mismatch between how the drug works and how patients think about it drives a significant share of early discontinuation.
The Dose Escalation Timeline
Before you even reach the maintenance phase, Wegovy requires a gradual dose increase over about four to five months. You start with the lowest dose and step up monthly through four intermediate doses before arriving at the full 2.4 mg weekly injection. Some people settle on a slightly lower maintenance dose of 1.7 mg if they can’t tolerate the highest level.
This escalation period is not optional. Jumping straight to the full dose causes significantly worse gastrointestinal side effects. So even if you’re eager to see results, the first several months are really about getting your body adjusted. Meaningful weight loss typically accelerates once you reach the maintenance dose and continues for roughly 12 to 16 months before plateauing.
What Happens If You Stop
If you stop Wegovy after reaching your goal, expect your appetite to return to its previous level within a few weeks. Most clinical data shows that people regain about two-thirds of the weight they lost within a year of stopping. This isn’t a failure of willpower. It reflects the biological reality that the drug was suppressing hunger signals your body still generates.
Some people manage to maintain a portion of their weight loss through diet and exercise habits they built while on the medication, but the odds are stacked against keeping all of it off. This is the core reason the FDA labels it for long-term use, and why most obesity medicine specialists recommend staying on it if you can access and afford it.
Insurance Renewal and Ongoing Coverage
If your insurance covers Wegovy, expect to re-qualify periodically. A common structure is review every six months, where your provider submits documentation showing you still meet the original criteria: a qualifying BMI or a lower BMI with a weight-related health condition. Some plans also require evidence that you’ve lost a minimum percentage of body weight (often 5%) within the first few months to justify continued coverage. If you plateau or regain weight, renewal can become more complicated, even though plateaus are a normal part of the process.